This site is intended for healthcare professionals

FDA approves Audenz for influenza A (H5N1).- Seqirus

Read time: 1 mins
Published:4th Feb 2020
Seqirus announced that the FDA has approved Audenz (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A (H5N1). Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.Comment: This is the first and only adjuvanted, cell-based pandemic vaccine to provide active immunization against the influenza A virus H5N1 strain. Seqirus has combined two leading-edge technologies—MF59 adjuvant and cell-based antigen manufacturing—to create this pandemic influenza vaccine. Audenz is designed to be rapidly deployed to help protect the U.S. population, and can be stockpiled for first responders in the event of pandemic.
Condition: Influenza
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.